10 September (Agence de Presse Medicale for Reuters Health)-British officials would neither confirm nor deny media reports that up to 3800 patients with hemophilia, other bleeding disorders, and primary immunodeficiency could have been exposed to variant Creutzfeldt-Jakob disease (vCJD) in blood products before these products were sourced from the United States.
"We are not giving any comment on the figures," a Health Department spokeswoman told Agence de Presse Medicale. "We think it is important to notify patients first."
The government said last month it was preparing to contact patients who received transfusions from donors who subsequently developed variant vCJD. The world's first possible case of vCJD transmission via transfusion was reported in the United Kingdom last December, followed by a second suspected case in July.
The Health Protection Agency (HPA) has conducted a risk assessment, but Ministers have refused to publish it until patients have been notified.
In a statement, Health Secretary John Reid said, "Although there are now 2 reports of possible transmission of vCJD via blood, the risk of transmission via plasma products, which will have been derived from large pools of plasma donated from many thousands of people-and therefore heavily diluted-is uncertain. But it cannot be excluded."
Reid said that the HPA had examined the risk associated with each batch of product and advised which patients needed to be assessed and possibly subsequently contacted. It had also advised how the possible risk to public health of those patients should be managed.
He said the HPA was sending infor-mation to clinicians to enable them to trace particular plasma products. The clinicians would then notify any patients identified as at risk as a precaution. Aside from patients with hemophilia or other bleeding disorders, the other main group of patients who might have received significant amounts of affected blood products is patients with primary immunodeficiency. Editor's comment. The vCJD epidemic in the United Kingdom related to the eating of beef has probably passed its peak. Only 1 new case of vCJD has been confirmed during the past 7 months. This brings the total number of new cases of vCJD during 2004 to 4, compared with 18 deaths during 2003 and a peak of 28 deaths in the year 2000. The total number of persons affected by vCJD (dead and alive) is 147.
However, now arises the question of the possibility of a second wave of cases related to receipt of blood products. Although the potential for this is frightening, one hopes that the risk will be so low that few, if any, cases will result.
MALARIA DRUG SHOWN EFFECTIVE AGAINST SARS
3 September (Reuters Health)-The antimalaria drug chloroquine could be used to treat severe acute respiratory syndrome (SARS), which killed hundreds of people last year, virologists at the Belgian Catholic University of Leuven (KUL) said.
A research team led by Professor Marc Van Ranst of KUL's Rega Institute for Medical Research found that chloroquine "is active against the SARS coronavirus in laboratory experiments."
"Chloroquine could be of great importance as preventive medication for people living in or travelling to SARS-affected areas, and as an antiviral treatment for SARS patients," the research team said in a statement.
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Editor's comment. Although these data are interesting, we need clinical trials to determine their relevance.
BIRD FLU KILLS THAI MAN, HIKES TOLL IN ASIA TO 29
9 September (Reuters Health)-The H5N1 strain of avian influenza has killed a young man in Thailand, raising the death toll from the virus in Asia to 29 this year, a Health Ministry official said on Thursday [9 September].
The man, who raised fighting cocks, fell ill last month and died early in September, Charal Trinwuthipong, head of the Department of Disease Control, told Reuters.
The virus, which spread through much of Asia earlier this year, has killed 20 people in Vietnam and 9 in Thailand.
Two Malaysians have been isolated in hospital this week with symptoms of bird flu after the illness emerged in Malaysia last month.
Victims are believed to have caught the virulent virus through close contact with sick poultry or their droppings.
Thailand was the world's fourth-largest chicken exporter until the disease forced the slaughter of 60 million birds and halted exports to key buyers Japan and Europe. Editor's comment. Articles like this are a constant reminder that avian influenza, capable of transmission from bird to human, is still with us. Fortunately, the current H5N1 strain has not been transmissible from person to person. However, it should be noted that, although human influenza has a high attack rate but a low mortality rate, H5N1 infection in humans has a low attack rate but, apparently, a very high mortality rate.
AIDS SHARPLY CUTS LIFE EXPECTANCY IN MOZAMBIQUE
3 September (Reuters Health [Mateus Chale])-AIDS has sharply reduced life expectancy in Mozambique and threatens to derail the government's reconstruction efforts after years of civil war, Health Ministry officials said on [3 September].
Life expectancy at birth this year was estimated at 38.1 years, compared with 46.4 if AIDS was absent, and could fall further to 35.9 years by 2010, the Health Ministry said in a report.
The Health Ministry report called for called for "immediate and effective" action to combat AIDS in a country where 1.4 million of the country's 18 million people live with AIDS.
It showed that prevalence of HIV jumped to 14.9% in the key 15-to 49year-old sexually active age group, from 13.6% in 2002.
It was projected to reach 16.8% in 5 years and would probably stabilize around those levels, the report said.
Urban centers, such as the port city of Beira, were badly affected, while remote rural districts were still virtually untouched by the disease, Health Ministry officials said-pointing to a prevalence rate of 35% in Beira, compared with 8.0% in northern districts near the Tanzania border.
Despite the worsening problem, Mo-zambique is one of the few southern African countries where prevalence is below 15%, activists say. In Zambia and Zimbabwe, 1 in every 5 adults carries HIV or has AIDS, while the prevalence in both Swaziland and Botswana is near 40%. Brazil has agreed to help Mozambique construct a company to manufacture cheap antiretrovirals (ARVs) in its enhanced fight against AIDS. Government officials say the possibility of South Africa and Zambia would also produce ARVs may help significantly cut the prices of drugs critical in AIDS management. Editor's comment. This and the following news item serve to remind us just how much of a problem HIV infection is in Africa, with many countries having prevalence rates of у20%. The response of these countries to the high cost of drugs used for the treatment of HIV infection is increasingly becoming construction of factories to produce generic versions of the agents.
ZAMBIA DECLARES AIDS EMERGENCY TO PRODUCE DRUGS
3 September (Reuters Health)-Zambia has declared HIV/AIDS a national emergency in a bid to start manufacturing generic AIDS drugs under World Trade Organization (WTO) rules, a senior gov-ernment official said on Friday [3 September].
One in every 5 Zambians is infected with HIV or has AIDS, which has orphaned more than 800,000 children and killed nearly 700,000 Zambians since the first case was reported in 1984.
Davidson Chilipamushi, the permanent secretary of commerce, trade, and industry, said the government had declared HIV/AIDS an emergency from August 2004 to July 2009 to enable local firms to obtain licenses to produce cheaper generic AIDS drugs.
The declaration would pave the way for the government to issue licenses to local firms to begin to manufacture generic AIDS drugs and it was already evaluating an application from local drugs manufacturing firm, Pharco Limited.
Patented western antiretroviral drugs cost between $300 and $1000 for a month's dosage in this southern African country of 10 million people, the majority of which live way below the World Bank poverty threshold of $1 per day.
Declaring HIV/AIDS an emergency is a requirement for developing countries, under a recent declaration on Trade Related Intellectual Properties Rights (TRIPS) at the WTO, to manufacture generic AIDS drugs strictly for local distribution.
